AnaptysBio ANAB
$46.63 −$0.77 (-1.62%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $46.63 0.00%
Open$47.49
Prev close$47.40
Day range$46.05 – $47.71
Volume432.5K
Market cap$1.39B
P/E (TTM)9.0
Dividend yield–
Fundamentals
Latest reported quarter: Q1, ended Sep 2026
Revenue$30.27M+18.5% YoY
Operating profit$19.91M+157.5% YoY
Net profit$3.88M+107.3% YoY
Diluted EPS$0.11+106.0% YoY
Free cash flow-$9.54M+63.2% YoY
Operating cash flow-$9.54M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin65.7%
Net margin12.8%
Current ratio8.40
Liabilities / assets93.2%
Cash & investments$152.99M
Total debt$10.36M
Net cash (debt)$142.63M
Income statement
| Line item | 2027 Q1 | 2026 ANNUAL | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $30.27M | $53.04M | $25.56M | $234.60M | $108.25M |
| Total Operating Revenue | $30.27M | $53.04M | $25.56M | $234.60M | $108.25M |
| Operating Expense | $10.37M | $20.72M | $60.19M | $7.70M | -$137.66M |
| Selling and Admin Expenses | $11.64M | $23.39M | $26.20M | $11.35M | -$23.60M |
| -General & Admin Expense | $11.64M | $23.39M | $26.20M | $11.35M | -$23.60M |
| Research & Development | -$1.27M | -$2.67M | $33.99M | -$3.64M | -$114.06M |
| Operating Profit | $19.91M | $32.32M | -$34.64M | $226.90M | $245.91M |
| Net Non-Operating Interest Income (Expense) | -$17.30M | -$37.94M | -$18.21M | -$70.08M | -$20.89M |
| Non-Operating Interest Income | $1.44M | $3.25M | $2.65M | $9.81M | -$1.18M |
| Non-Operating Interest Expense | $18.74M | $41.19M | $20.86M | $79.89M | $19.71M |
| Other Income (Expense) | $667,000.00 | $525,000.00 | -$1,000.00 | $5.45M | $20,000.00 |
| Other Non-Operating Income (Expenses) | $667,000.00 | $525,000.00 | -$1,000.00 | $5.45M | $20,000.00 |
| Pretax Profit | $3.27M | -$5.09M | -$52.84M | $162.28M | $225.04M |
| Tax | -$608,000.00 | -$181.45M | $40,000.00 | $772,000.00 | $689,000.00 |
| Net Profit | $3.88M | $131.00M | -$52.88M | -$13.23M | $49.61M |
| Profit from Continuing Operations | $3.88M | $176.36M | -$52.88M | $161.50M | $224.35M |
| Net Income from Discontinuous Operations | $0.00 | -$45.36M | – | -$174.74M | – |
| Net Income to Parent Company | $3.88M | $131.00M | -$52.88M | -$13.23M | $49.61M |
| Net Income to Common Stockholders | $3.88M | $131.00M | -$52.88M | -$13.23M | $49.61M |
| Basic EPS | $0.13 | $4.52 | -$1.84 | -$0.46 | $1.79 |
| Diluted EPS | $0.11 | $3.50 | -$1.84 | -$0.46 | $1.58 |
Balance sheet
| Line item | 2027 Q1 | 2026 ANNUAL | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $307.04M | $316.98M | $329.68M | $364.40M | $364.40M |
| Total Current Assets | $188.37M | $198.43M | $316.11M | $350.25M | $350.25M |
| Cash and Cash Equivalents & Short-Term Investments | $152.99M | $164.14M | $286.46M | $211.64M | $211.64M |
| -Cash and Cash Equivalents | $135.39M | $133.83M | $248.47M | $138.20M | $138.20M |
| -Short Term Investments | $17.60M | $30.32M | $37.99M | $73.44M | $73.44M |
| Receivables | $34.00M | $25.63M | $25.75M | $33.85M | $33.85M |
| -Accounts Receivable | $30.49M | $25.63M | $25.75M | $33.85M | $33.85M |
| -Taxes Receivable | $3.28M | – | – | – | – |
| -Other Receivables | $220,000.00 | – | – | – | – |
| Prepaid Assets | $1.38M | – | – | – | – |
| Total Non-Current Assets | $118.67M | $118.56M | $13.58M | $14.15M | $14.15M |
| Net PPE | $11.17M | $11.66M | $13.32M | $12.63M | $12.63M |
| -Gross PPE | $11.27M | $11.76M | $20.59M | $12.72M | $12.72M |
| -Accumulated Depreciation | -$106,000.00 | -$101,000.00 | -$7.27M | -$92,000.00 | -$92,000.00 |
| Non-Current Deferred Assets | $107.25M | $106.64M | – | $0.00 | $0.00 |
| Other Non-Current Assets | $256,000.00 | $256,000.00 | $256,000.00 | $1.52M | $1.52M |
| Total Liabilities | $286.22M | $306.40M | $316.94M | $327.19M | $327.19M |
| Total Current Liabilities | $22.42M | $35.35M | $41.70M | $38.63M | $38.63M |
| Payables | $879,000.00 | $4.39M | $7.52M | $3.87M | $3.87M |
| -Accounts Payable | $879,000.00 | $4.39M | $7.52M | $3.87M | $3.87M |
| Current Accrued Expenses | $14.95M | $22.93M | $26.53M | $21.58M | $21.58M |
| Short-Term Debt and Capital Lease Obligation | $2.20M | $2.16M | $2.12M | $2.08M | $2.08M |
| -Current Capital Lease Obligation | $2.20M | $2.16M | $2.12M | $2.08M | $2.08M |
| Total Non-Current Liabilities | $263.80M | $271.05M | $275.24M | $288.56M | $288.56M |
| Long Term Accounts Payable and Other Payables | $3.62M | $3.62M | – | $0.00 | $0.00 |
| Long Term Debt and Capital Lease Obligation | $10.36M | $10.93M | $11.49M | $12.03M | $12.03M |
| -Long Term Capital Lease Obligation | $10.36M | $10.93M | $11.49M | $12.03M | $12.03M |
| Other Non-Current Liabilities | $249.82M | $256.49M | $263.74M | $276.53M | $276.53M |
| Total Equity | $20.82M | $10.59M | $12.75M | $37.21M | $37.21M |
| Stockholders' Equity | $20.82M | $10.59M | $12.75M | $37.21M | $37.21M |
| Capital Stock | $30,000.00 | $30,000.00 | $29,000.00 | $28,000.00 | $28,000.00 |
| -Common Stock | $30,000.00 | $30,000.00 | $29,000.00 | $28,000.00 | $28,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $658.66M | $652.27M | $838.31M | $809.77M | $809.77M |
| Retained Earnings | -$637.69M | -$641.56M | -$825.44M | -$772.56M | -$772.56M |
| Gains/Losses Not Affecting Retained Earnings | -$181,000.00 | -$151,000.00 | -$146,000.00 | -$24,000.00 | -$24,000.00 |
| Other Current Assets | – | $8.65M | $3.91M | – | – |
| Investments and Advances | – | $0.00 | – | $0.00 | $0.00 |
Cash flow
| Line item | 2027 Q1 | 2026 ANNUAL | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$9.54M | -$52.56M | -$25.92M | $19.70M | $98.00M |
| Net cash flow from continuing operations | -$9.54M | -$1.40M | -$25.92M | $161.79M | $240.09M |
| Net Income from Continuing Operations | $3.88M | $176.36M | -$52.88M | $161.50M | $224.35M |
| Gain/Loss from Continuing Operations | $18.74M | $41.19M | – | $79.89M | – |
| Depreciation & Depletion & Amortization | $495,000.00 | $968,000.00 | $610,000.00 | $1.88M | $67,000.00 |
| Deferred Tax | -$608,000.00 | -$183.70M | – | $0.00 | – |
| Change in Working Capital | -$35.17M | -$44.57M | -$8.71M | -$80.53M | $20.10M |
| -Change in Receivables | -$4.86M | $4.97M | $8.10M | $6.92M | $41.84M |
| -Change in Prepaid Assets | $2.69M | -$3.67M | $1.50M | $1.81M | $1.17M |
| -Change in Payables and Accrued Expense | -$32.47M | -$44.85M | -$17.82M | -$87.33M | -$22.42M |
| -Change in Other Current Liabilities | -$528,000.00 | -$1.02M | -$499,000.00 | -$1.93M | -$494,000.00 |
| Cash Flow from Discontinued Operating Activities | $0.00 | -$51.16M | – | -$142.09M | – |
| Net cash flow from investing | $12.59M | $42.55M | $34.98M | $228.03M | $73.50M |
| Net Cash Flow from Continuing Investing Activities | $12.59M | $42.55M | $34.98M | $228.12M | $73.59M |
| Net Investment Purchase and Sale | $12.59M | $42.55M | $35.00M | $228.12M | $73.50M |
| Financing Cash Flow | -$1.48M | -$94.36M | $1.21M | -$132.61M | -$43.13M |
| Net Cash Flow from Continuing Financing Activities | -$1.48M | $5.64M | $1.21M | -$132.61M | -$43.13M |
| Net Common Stock Issuance | $4.44M | $25.37M | $14.02M | -$54.37M | $8.83M |
| Net Other Financing Charges | -$5.92M | -$19.73M | -$12.81M | -$76.80M | -$51.96M |
| Ending Cash Balance | $135.39M | $133.83M | $248.47M | $138.20M | $138.20M |
| Net Change in Cash | $1.57M | -$104.37M | $10.27M | $115.12M | $128.36M |
| Beginning Cash Balance | $133.83M | $238.20M | $238.20M | $23.08M | $109.83M |
| Free Cash Flow | -$9.54M | -$52.56M | -$25.94M | $19.70M | $98.08M |
| Proceeds from Stock Option Exercised | – | $0.00 | $0.00 | -$1.45M | $0.00 |
| Cash Flow from Discontinued Financing Activities | – | -$100.00M | – | $0.00 | – |
| Other Non-Cash Items | – | – | $20.86M | – | – |
| Net PPE Purchase and Sale | – | – | -$17,000.00 | – | – |
No comments yet — be the first to weigh in on ANAB.
Sign in to join the discussion.